Abstract:Abstract Eosinophils are a critical type of immune cell and central players in type 2 immunity. Existing literature suggests that eosinophils also can play a role in host antiviral responses, typically type 1 immune events, against multiple respiratory viruses, both directly through release of antiviral mediators and indirectly through activation of other effector cell types. One way to prime host immune responses toward effective antiviral responses is through vaccination, where typically a type 1–skewed immunity is desirable in the context of intracellular pathogens like respiratory viruses. In the realm of breakthrough respiratory viral infection in vaccinated hosts, an event in which virus can still establish productive infection despite preexisting immunity, eosinophils are most prominently known for their link to vaccine-associated enhanced respiratory disease upon natural respiratory syncytial virus infection. This was observed in a pediatric cohort during the 1960s following vaccination with formalin-inactivated respiratory syncytial virus. More recent research has unveiled additional roles of the eosinophil in respiratory viral infection and breakthrough infection. The specific contribution of eosinophils to the quality of vaccine responses, vaccine efficacy, and antiviral responses to infection in vaccinated hosts remains largely unexplored, especially regarding their potential roles in protection. On the basis of current findings, we will speculate upon the suggested function of eosinophils and consider the many potential ways by which eosinophils may exert protective and pathological effects in breakthrough infections. We will also discuss how to balance vaccine efficacy with eosinophil-related risks, as well as the use of eosinophils and their products as potential biomarkers of vaccine efficacy or adverse events.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is about the role of eosinophils in respiratory virus vaccination and subsequent breakthrough infections. Specifically, the paper explores the possible protective or pathological roles that eosinophils may play during the vaccination process and when encountering viruses after vaccination. The following is a detailed analysis of the core issues in the paper: 1. **The role of eosinophils in vaccination**: - Eosinophils are usually associated with type 2 immune responses, but they may also be involved in type 1 immune responses. - During the vaccination process, eosinophils may be recruited to the injection site and influence the polarization direction of T cells by secreting cytokines such as IL - 4 and IFN - γ. - Eosinophils may also migrate to lymph nodes, spleen and bone marrow, interact with B cells and long - lived plasma cells (LLPCs), and promote antibody production and maintenance. 2. **The role of eosinophils in breakthrough infections**: - Even after vaccination, breakthrough infections may still occur due to reasons such as a decline in antibody titers and viral antigen variation. - In breakthrough infections, eosinophils may play a protective role, for example, by directly killing virus - infected cells or activating other effector cells. - On the other hand, eosinophils may also cause pathological reactions, such as vaccine - associated enhanced respiratory disease (VAERD), manifested as excessive production of type 2 cytokines, lung inflammation and excessive mucus secretion, etc. 3. **Balancing vaccine efficacy and eosinophil - related risks**: - The paper discusses how to balance type 1 and type 2 immune responses in vaccine design to maximize the protective effect of the vaccine while minimizing potential adverse reactions. - Eosinophils and their products may serve as biomarkers of vaccine efficacy or adverse events for monitoring and evaluating the effectiveness of vaccines. In summary, this paper aims to comprehensively analyze the complex role of eosinophils in respiratory virus vaccination and breakthrough infections, explore their potential protective mechanisms and pathological effects, and propose how to optimize vaccine design to achieve the best immune protection.

Ally, adversary, or arbitrator? The context-dependent role of eosinophils in vaccination for respiratory viruses and subsequent breakthrough infections